Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor. Data generated from the analysis are expected to expand the understanding of multiple myeloma biology and potentially identify mechanisms of sensitivity or resistance to proteasome inhibitor treatment, which will inform and improve future therapies. The pivotal Phase 3 clinical trial, known as TOURMALINE-MM1, compared NINLARO combined with lenalidomide and dexamethasone to placebo plus lenalidomide and dexamethasone. The trial involved collection of tumor plasma cells from patients when they enrolled into the trial and from patients whose disease reappeared after initial response or progressed during treatment.

Hundreds of these samples were profiled by RNA sequencing and DNA mutational analysis using a targeted panel interrogating 754 genes. The panel was designed by Takeda in collaboration with the Broad Institute and run through the Broad Institute'sCLIA approved, CAP accredited laboratory. The pivotal Phase 3 clinical trial, known as TOURMALINE-MM1, compared NINLARO combined with lenalidomide and dexamethasone to placebo plus lenalidomide and dexamethasone. The trial involved collection of tumor plasma cells from patients when they enrolled into the trial and from patients whose disease reappeared after initial response or progressed during treatment.

Hundreds of these samples were profiled by RNA sequencing and DNA mutational analysis using a targeted panel interrogating 754 genes. The panel was designed by Takeda in collaboration with the Broad Institute and run through the Broad Institute'sCLIA approved, CAP accredited laboratory.